Erratum: Reversing multidrug resistance in caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides (PLoS ONE (2014) 9: 3 (E90180) DOI: 10.1371/journal.pone.0090180);Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lo, Yu Li ^a   Liu, Yu ^a  

^a NATIONAL UNIVERSITY OF TAINAN   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR; DIOLEOYL PHOSPHOTIDYLETHANOLAMINE; EPIRUBICIN; LIPOSOME; MACROGOL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; N [1 (2,3 DIOLEYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM CHLORIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; UNCLASSIFIED DRUG; CASPASE; MACROGOL DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON ADENOCARCINOMA; DRUG FORMULATION; DRUG RETENTION; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPOSOMAL GENE DELIVERY SYSTEM; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOMEDICINE; PARTICLE SIZE; SIGNAL TRANSDUCTION; CACO 2 CELL LINE; CELL CYCLE; CHEMISTRY; DNA FRAGMENTATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PROMOTER REGION; REPORTER GENE; TOXICITY;

APOPTOSIS; BCL-X PROTEIN; CACO-2 CELLS; CASPASES; CELL CYCLE; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, REPORTER; HUMANS; LIPOSOMES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER;

EID: 84898639619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112604     Document Type: Erratum

References (43)

1. Lage H (2008) An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65: 3145-3167.
2. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Salagacka A, et al. (2010) ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 25: 1167-1176.
3. He T, Mo A, Zhang K, Liu L (2013) ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies. Colorectal Dis 15: 12-18.
4. Wang X, Wang C, Qin YW, Yan SK, Gao YR (2007) Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. Leuk Res 31: 989-994. (Pubitemid 46856717)
5. Lo YL (2013) A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma caco-2 cells. Int J Mol Sci 14: 158-176.
6. Falkson G, Vorobiof DA (1984) Epirubicin in colorectal cancer. In: Bonadonna G, editor. Advances in Anthracycline Chemotherapy: Epirubicin. Masson: Italia Editori. pp. 105-109.
7. Plosker GL, Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45: 788-856. (Pubitemid 23177452)
8. Marbeuf-Gueye C, Salerno M, Quidu P, Garnier-Suillerot A (2000) Inhibition of the P-glycoprotein-and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 391: 207-216. (Pubitemid 30154086)
9. Lo YL, Wang W, Ho CT (2012) 7,39,49-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology 302: 221-232.
10. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, et al. (2005) A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698. (Pubitemid 41685303)
11. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, et al. (2006) Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int 97: 1300-1308. (Pubitemid 43907340)
12. Lo YL, Ho CT, Tsai FL (2008) Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci 35: 52-67.
13. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) Pglycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9: 1266-1272. (Pubitemid 35331774)
14. Minko T, Dharap SS, Pakunlu RI, Wang Y (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5: 389-406. (Pubitemid 38559349)
15. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, et al. (2006) In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 114: 153-162. (Pubitemid 44291853)
16. Watts JK, Corey DR (2012) Silencing disease genes in the laboratory and the clinic. J Pathol 226: 365-379.
17. Dean NM, Bennett CF (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22: 9087-9096. (Pubitemid 38121709)
18. Rayburn ER, Wang H, Zhang R (2006) Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 11: 337-352. (Pubitemid 43723312)
19. Marwick C (1998) First ''antisense'' drug will treat CMV retinitis. JAMA 280: 871. (Pubitemid 28423898)
20. Nakagawa O, Ming X, Huang L, Juliano RL (2010) Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc 132: 8848-8849.
21. Li SD, Huang L (2006) Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3: 579-588. (Pubitemid 44639135)
22. Perouzel E, Jorgensen MR, Keller M, Miller AD (2003) Synthesis and formulation of neoglycolipids for the functionalization of liposomes and lipoplexes. Bioconjug Chem 14: 884-898. (Pubitemid 37152947)
23. Lo YL (2003) Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 90: 37-48.
24. Lania L, Majello B, De Luca P (1997) Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol 29: 1313-1323. (Pubitemid 28153485)
25. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, et al. (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311: 1179-1187. (Pubitemid 39612726)
26. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC (1999) Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 53: 229-240. (Pubitemid 29209892)
27. Makhey VD, Guo A, Norris DA, Hu P, Yan J, et al. (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15: 1160-1167. (Pubitemid 28401704)
28. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, et al. (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299: 164-170. (Pubitemid 32905131)
29. Ray RM, Bhattacharya S, Johnson LR (2011) Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 16: 35-44.
30. Liu D, Hu Q, Song YK (1995) Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1240: 277-284. (Pubitemid 26004752)
31. Zhang W, Shi Y, Chen Y, Hao J, Sha X, et al. (2011) The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials 32: 5934-5944.
32. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26: 57-64.
33. Lo YL, Liu Y, Tsai JC (2013) Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomed Pharmacother 67: 261-267.
34. Bargonetti J, Manfredi JJ (2002) Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91. (Pubitemid 34072969)
35. Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, et al. (2003) Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94: 394-399. (Pubitemid 36636907)
36. Shabbits JA, Hu Y, Mayer LD (2003) Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2: 805-813.
37. Men Y, Wang XX, Li RJ, Zhang Y, Tian W, et al. (2011) The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Int J Nanomedicine 6: 3125-3137.
38. Zhou L, He XD, Yu JC, Zhou RL, Shan Y, et al. (2011) Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery 150: 25-31.
39. Minko T, Batrakova EV, Li S, Li Y, Pakunlu RI, et al. (2005) Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 105: 269-278. (Pubitemid 40941992)
40. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, et al. (2003) Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9: 33-41.
41. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J (2003) Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 106: 108-115. (Pubitemid 36750396)
42. Campone M, Vavasseur F, Le Cabellec MT, Meflah K, Vallette FM, et al. (2001) Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 15: 1377-1387. (Pubitemid 32785307)
43. Altundag K, Altundag O, Gunduz M, Arun B (2012) Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen. Med Hypotheses 63: 823-826.